Squarepoint Ops LLC Decreases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Squarepoint Ops LLC cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 34.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,374 shares of the company's stock after selling 25,151 shares during the quarter. Squarepoint Ops LLC owned 0.07% of Kymera Therapeutics worth $1,946,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Natixis Advisors LLC acquired a new position in Kymera Therapeutics during the third quarter worth $681,000. Thrivent Financial for Lutherans purchased a new position in shares of Kymera Therapeutics in the third quarter valued at $313,000. Intech Investment Management LLC acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth $650,000. Massachusetts Financial Services Co. MA boosted its position in shares of Kymera Therapeutics by 11.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company's stock worth $21,458,000 after buying an additional 47,507 shares in the last quarter. Finally, FMR LLC grew its stake in Kymera Therapeutics by 5.8% in the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company's stock valued at $241,816,000 after acquiring an additional 282,301 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have issued reports on KYMR. HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Stephens reissued an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. BTIG Research initiated coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, Leerink Partners reiterated an "outperform" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Remove Ads

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,788 shares of company stock worth $455,202 in the last three months. 15.82% of the stock is currently owned by company insiders.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock traded down $0.58 during trading on Friday, reaching $29.62. The company had a trading volume of 357,093 shares, compared to its average volume of 522,181. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -12.66 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12-month low of $29.07 and a 12-month high of $53.27. The stock's 50 day moving average price is $35.86 and its two-hundred day moving average price is $41.77.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.